{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T09:25:12Z","timestamp":1758273912938},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s00105-023-05258-8","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T09:14:42Z","timestamp":1702372482000},"page":"75-86","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Mastozytose \u2013 eine h\u00e4ufig unerkannte Erkrankung","Mastocytosis\u2014a\u00a0frequently unrecognized disease"],"prefix":"10.1007","volume":"75","author":[{"given":"Melba","family":"Mu\u00f1oz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Siebenhaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"issue":"788","key":"5258_CR1","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1136\/bmj.1.788.161","volume":"1","author":"E Nettleship","year":"1876","unstructured":"Nettleship\u00a0E (1876) Unusual distribution of retinal blood-vessels: three cases. Br Med\u00a0J 1(788):161\u2013162","journal-title":"Br Med J"},{"issue":"5","key":"5258_CR2","first-page":"426","volume":"48","author":"JM Ellis","year":"1949","unstructured":"Ellis\u00a0JM (1949) Urticaria pigmentosa; a\u00a0report of a\u00a0case with autopsy. Arch Pathol (Chic) 48(5):426\u2013435","journal-title":"Arch Pathol (Chic)"},{"issue":"7","key":"5258_CR3","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1038\/nri3690","volume":"14","author":"S Wernersson","year":"2014","unstructured":"Wernersson\u00a0S, Pejler\u00a0G (2014) Mast cell secretory granules: armed for battle. Nat Rev Immunol 14(7):478\u2013494","journal-title":"Nat Rev Immunol"},{"key":"5258_CR4","first-page":"1","volume":"34","author":"SJ Galli","year":"1984","unstructured":"Galli\u00a0SJ, Dvorak\u00a0AM, Dvorak\u00a0HF (1984) Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy 34:1\u2013141","journal-title":"Prog Allergy"},{"issue":"23","key":"5258_CR5","doi-asserted-by":"publisher","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","volume":"92","author":"H Nagata","year":"1995","unstructured":"Nagata\u00a0H et al (1995) Identification of a\u00a0point mutation in the catalytic domain of the protooncogene c\u2011kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S\u00a0A 92(23):10560\u201310564","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"5258_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.jaci.2015.08.034","volume":"137","author":"K Hartmann","year":"2016","unstructured":"Hartmann\u00a0K et\u00a0al (2016) Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma & Immunology; and the European Academy of Allergology and Clinical Immunology. J\u00a0Allergy Clin Immunol 137(1):35\u201345","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"5258_CR7","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.iac.2014.01.003","volume":"34","author":"K Brockow","year":"2014","unstructured":"Brockow\u00a0K (2014) Epidemiology, prognosis, and risk factors in mastocytosis. Immunol Allergy Clin North Am 34(2):283\u2013295","journal-title":"Immunol Allergy Clin North Am"},{"issue":"3","key":"5258_CR8","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bjd.13567","volume":"172","author":"C Meni","year":"2015","unstructured":"Meni\u00a0C et\u00a0al (2015) Paediatric mastocytosis: a\u00a0systematic review of 1747 cases. Br J Dermatol 172(3):642\u2013651","journal-title":"Br J Dermatol"},{"issue":"7","key":"5258_CR9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0145-2126(01)00044-3","volume":"25","author":"K Wolff","year":"2001","unstructured":"Wolff\u00a0K, Komar\u00a0M, Petzelbauer\u00a0P (2001) Clinical and histopathological aspects of cutaneous mastocytosis. Leuk Res 25(7):519\u2013528","journal-title":"Leuk Res"},{"issue":"1","key":"5258_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/modpathol.2013.117","volume":"27","author":"S Berezowska","year":"2014","unstructured":"Berezowska\u00a0S et al (2014) Adult-onset mastocytosis in the skin is highly suggestive of systemic mastocytosis. Mod Pathol 27(1):19\u201329","journal-title":"Mod Pathol"},{"issue":"7","key":"5258_CR11","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","volume":"94","author":"AS Kirshenbaum","year":"1999","unstructured":"Kirshenbaum\u00a0AS et al (1999) Demonstration that human mast cells arise from a\u00a0progenitor cell population that is CD34(+), c\u2011kit(+), and expresses aminopeptidase N (CD13). Blood 94(7):2333\u20132342","journal-title":"Blood"},{"issue":"9","key":"5258_CR12","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1182\/blood.V80.9.2237.2237","volume":"80","author":"P Valent","year":"1992","unstructured":"Valent\u00a0P et al (1992) Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor\/kit-ligand in long-term culture. Blood 80(9):2237\u20132245","journal-title":"Blood"},{"issue":"6","key":"5258_CR13","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/leu.2010.69","volume":"24","author":"A Tefferi","year":"2010","unstructured":"Tefferi\u00a0A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia 24(6):1128\u20131138","journal-title":"Leukemia"},{"issue":"14","key":"5258_CR14","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","volume":"122","author":"J Schwaab","year":"2013","unstructured":"Schwaab\u00a0J et\u00a0al (2013) Comprehensive mutational profiling in advanced systemic mastocytosis. Blood 122(14):2460\u20132466","journal-title":"Blood"},{"issue":"1","key":"5258_CR15","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40364-023-00468-7","volume":"11","author":"M Mancini","year":"2023","unstructured":"Mancini\u00a0M et\u00a0al (2023) SETD2 non genomic loss of function in advanced systemic mastocytosis is mediated by an Aurora kinase A\/MDM2 axis and can be therapeutically targeted. Biomark Res 11(1):29","journal-title":"Biomark Res"},{"issue":"3","key":"5258_CR16","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1038\/jid.2009.281","volume":"130","author":"C Bodemer","year":"2010","unstructured":"Bodemer\u00a0C et al (2010) Pediatric mastocytosis is a\u00a0clonal disease associated with D816V and other activating c\u2011KIT mutations. J\u00a0Invest Dermatol 130(3):804\u2013815","journal-title":"J Invest Dermatol"},{"issue":"6","key":"5258_CR17","doi-asserted-by":"publisher","first-page":"e348","DOI":"10.1111\/pde.13651","volume":"35","author":"AM Hosking","year":"2018","unstructured":"Hosking\u00a0AM et\u00a0al (2018) Diffuse cutaneous mastocytosis: case report and literature review. Pediatr Dermatol 35(6):e348\u2013e352","journal-title":"Pediatr Dermatol"},{"issue":"2","key":"5258_CR18","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/j.1365-2230.2007.02585.x","volume":"33","author":"NK Webber","year":"2008","unstructured":"Webber\u00a0NK, Ponnampalam\u00a0J, Grattan\u00a0CE (2008) How reliable is blood tryptase as a\u00a0marker of systemic disease in an infant with cutaneous mastocytomas? Clin Exp Dermatol 33(2):198\u2013199","journal-title":"Clin Exp Dermatol"},{"issue":"11","key":"5258_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","volume":"140","author":"DA Arber","year":"2022","unstructured":"Arber\u00a0DA et\u00a0al (2022) International consensus classification of Myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood 140(11):1200\u20131228","journal-title":"Blood"},{"issue":"6","key":"5258_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1097\/00006842-198607000-00006","volume":"48","author":"MP Rogers","year":"1986","unstructured":"Rogers\u00a0MP et\u00a0al (1986) Mixed organic brain syndrome as a\u00a0manifestation of systemic mastocytosis. Psychosom Med 48(6):437\u2013447","journal-title":"Psychosom Med"},{"issue":"12","key":"5258_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1038\/modpathol.2008.158","volume":"21","author":"R Kirsch","year":"2008","unstructured":"Kirsch\u00a0R et\u00a0al (2008) Systemic mastocytosis involving the gastrointestinal tract: clinicopathologic and molecular study of five cases. Mod Pathol 21(12):1508\u20131516","journal-title":"Mod Pathol"},{"issue":"6","key":"5258_CR22","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.annemergmed.2005.02.002","volume":"45","author":"SM Rohr","year":"2005","unstructured":"Rohr\u00a0SM, Rich\u00a0MW, Silver\u00a0KH (2005) Shortness of breath, syncope, and cardiac arrest caused by systemic mastocytosis. Ann Emerg Med 45(6):592\u2013594","journal-title":"Ann Emerg Med"},{"issue":"2","key":"5258_CR23","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1398-9995.2007.01569.x","volume":"63","author":"K Brockow","year":"2008","unstructured":"Brockow\u00a0K et\u00a0al (2008) Anaphylaxis in patients with mastocytosis: a\u00a0study on history, clinical features and risk factors in 120 patients. Allergy 63(2):226\u2013232","journal-title":"Allergy"},{"issue":"11","key":"5258_CR24","doi-asserted-by":"publisher","first-page":"e646","DOI":"10.1097\/HS9.0000000000000646","volume":"5","author":"P Valent","year":"2021","unstructured":"Valent\u00a0P et\u00a0al (2021) Updated Diagnostic Criteria and Classification of Mast Cell Disorders: A\u00a0Consensus Proposal. Hemasphere 5(11):e646","journal-title":"Hemasphere"},{"issue":"8","key":"5258_CR25","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1111\/all.14248","volume":"75","author":"J Trizuljak","year":"2020","unstructured":"Trizuljak\u00a0J et\u00a0al (2020) Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification. Allergy 75(8):1927\u20131938","journal-title":"Allergy"},{"issue":"7","key":"5258_CR26","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/ajh.24382","volume":"91","author":"L Pieri","year":"2016","unstructured":"Pieri\u00a0L et\u00a0al (2016) Clinical presentation and management practice of systemic mastocytosis. A\u00a0survey on 460 Italian patients. Am J Hematol 91(7):692\u2013699","journal-title":"Am J Hematol"},{"issue":"21","key":"5258_CR27","doi-asserted-by":"publisher","first-page":"5750","DOI":"10.1182\/bloodadvances.2022007539","volume":"6","author":"A Reiter","year":"2022","unstructured":"Reiter\u00a0A et\u00a0al (2022) Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis. Blood Adv 6(21):5750\u20135762","journal-title":"Blood Adv"},{"issue":"13","key":"5258_CR28","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.2217\/fon-2021-1509","volume":"18","author":"H Pilkington","year":"2022","unstructured":"Pilkington\u00a0H et\u00a0al (2022) Indirect treatment comparisons of avapritinib versus midostaurin for patients with advanced systemic mastocytosis. Future Oncol 18(13):1583\u20131594","journal-title":"Future Oncol"},{"issue":"12","key":"5258_CR29","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1038\/ng.3696","volume":"48","author":"JJ Lyons","year":"2016","unstructured":"Lyons\u00a0JJ et\u00a0al (2016) Elevated basal serum tryptase identifies a\u00a0multisystem disorder associated with increased TPSAB1 copy number. Nat Genet 48(12):1564\u20131569","journal-title":"Nat Genet"},{"issue":"9","key":"5258_CR30","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1016\/j.jaip.2021.12.031","volume":"10","author":"AM Waters","year":"2022","unstructured":"Waters\u00a0AM et\u00a0al (2022) Elevated Basal Serum Tryptase: Disease Distribution and Variability in a\u00a0Regional Health System. J\u00a0Allergy Clin Immunol Pract 10(9):2424\u20132435 (e5)","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"10","key":"5258_CR31","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1016\/j.jaip.2023.08.008","volume":"11","author":"P Valent","year":"2023","unstructured":"Valent\u00a0P et\u00a0al (2023) The normal range of baseline tryptase should be 1 to 15\u202fng\/mL and covers healthy individuals with HalphaT. J\u00a0Allergy Clin Immunol Pract 11(10):3010\u20133020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"5258_CR32","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1016\/j.jaci.2020.06.035","volume":"147","author":"JJ Lyons","year":"2021","unstructured":"Lyons\u00a0JJ et al (2021) Heritable risk for severe anaphylaxis associated with increased alpha-tryptase-encoding germline copy number at TPSAB1. J\u00a0Allergy Clin Immunol 147(2):622\u2013632","journal-title":"J Allergy Clin Immunol"},{"issue":"8","key":"5258_CR33","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1016\/j.jaip.2022.04.041","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent\u00a0P et\u00a0al (2022) Recent developments in the field of mast cell disorders: classification, prognostication, and management. J\u00a0Allergy Clin Immunol Pract 10(8):2052\u20132055","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"6","key":"5258_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1111\/cea.13592","volume":"50","author":"F Jendoubi","year":"2020","unstructured":"Jendoubi\u00a0F et\u00a0al (2020) Omalizumab in the treatment of adult patients with mastocytosis: a\u00a0systematic review. Clin Exp Allergy 50(6):654\u2013661","journal-title":"Clin Exp Allergy"},{"issue":"6","key":"5258_CR35","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1111\/j.1398-9995.2012.02812.x","volume":"67","author":"I Alvarez-Twose","year":"2012","unstructured":"Alvarez-Twose\u00a0I et al (2012) Increased serum baseline tryptase levels and extensive skin involvement are predictors for the severity of mast cell activation episodes in children with mastocytosis. Allergy 67(6):813\u2013821","journal-title":"Allergy"},{"issue":"8","key":"5258_CR36","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1016\/j.jaip.2022.03.007","volume":"10","author":"P Valent","year":"2022","unstructured":"Valent\u00a0P et al (2022) Personalized management strategies in mast cell disorders: ECNM-AIM user\u2019s guide for daily clinical practice. J\u00a0Allergy Clin Immunol Pract 10(8):1999\u20132012 (e6)","journal-title":"J Allergy Clin Immunol Pract"},{"key":"5258_CR37","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/978-3-319-91439-8_10","volume":"212","author":"RF Schlenk","year":"2018","unstructured":"Schlenk\u00a0RF, Kayser Midostaurin\u00a0S (2018) A\u00a0multiple Tyrosine Kinases inhibitor in acute myeloid leukemia and systemic mastocytosis. Recent Results Cancer Res 212:199\u2013214","journal-title":"Recent Results Cancer Res"},{"issue":"15","key":"5258_CR38","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1182\/blood.2021014612","volume":"140","author":"J Gotlib","year":"2022","unstructured":"Gotlib\u00a0J, Reiter\u00a0A, DeAngelo\u00a0DJ (2022) Avapritinib for advanced systemic mastocytosis. Blood 140(15):1667\u20131673","journal-title":"Blood"},{"issue":"6","key":"5258_CR39","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1016\/j.jaci.2022.04.020","volume":"149","author":"C Akin","year":"2022","unstructured":"Akin\u00a0C, Arock\u00a0M, Valent\u00a0P (2022) Tyrosine kinase inhibitors for the treatment of indolent systemic mastocytosis: are we there yet? J\u00a0Allergy Clin Immunol 149(6):1912\u20131918","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"5258_CR40","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/all.12842","volume":"71","author":"F Siebenhaar","year":"2016","unstructured":"Siebenhaar F, von Tschirnhaus E, Hartmann K, Rabenhorst A, Staubach P, Peveling-Oberhag A, Wagner N, Martus P, Carter MC, Metcalfe DD, Church MK, Maurer M, Weller K (2016) Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. Allergy 71(6):869\u2013877","journal-title":"Allergy"},{"issue":"7","key":"5258_CR41","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1111\/all.13425","volume":"73","author":"F Siebenhaar","year":"2018","unstructured":"Siebenhaar F, Sander B, Ho LHT, Ellrich A, Maurer M, Weller K (2018) Development and validation of the mastocytosis activity score. Allergy 73(7):1489\u20131496","journal-title":"Allergy"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05258-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-023-05258-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-023-05258-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T09:04:35Z","timestamp":1704963875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-023-05258-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["5258"],"URL":"https:\/\/doi.org\/10.1007\/s00105-023-05258-8","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"assertion":[{"value":"26 October 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autorinnen und Autoren sowie die Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"<b>M.\u00a0Mu\u00f1oz<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Takeda, Novartis, Blueprint. \u2013\u00a0Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Takeda, Novartis, Blueprint.\u00a0\u2013 Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Takeda, Novartis, Sanofi. \u2013\u00a0B.\u00a0Nichtfinanzielle Interessen: Angestellte Dermatologin und Allergologin, Institut f\u00fcr Allergieforschung, Charit\u00e9-Universit\u00e4tsmedizin Berlin und Fraunhofer ITMP Immunology and Allergology IA | Mitgliedschaften: Deutsche Gesellschaft f\u00fcr Immunologie (DGfI), European Society of Dermatological Research Academy (ESDR). <b>F.\u00a0Siebenhaar<\/b>: A.\u00a0Finanzielle Interessen: Forschungsf\u00f6rderung zur pers\u00f6nlichen Verf\u00fcgung: Allakos, Blueprint, Celldex, Cogent, Granular, Novartis, Third Harmonic Bio.\u00a0\u2013 Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Blueprint, Noucor, Novartis, Sanofi\/Regeneron. \u2013\u00a0Bezahlte Beratungsleistungen, interne Schulungsvortr\u00e4ge, Gehaltsbezug o.\u202f\u00c4.: Blueprint, Cogent, Escient, Granular, GSK, Invea, Noucor, Novartis.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: Bereichsleiter Hochschulambulanz Allergologie, Institut f\u00fcr Allergieforschung, Charit\u00e9-Universit\u00e4tsmedizin Berlin; Bereichsleiter Pr\u00e4klinische Forschung, Fraunhofer Institut f\u00fcr Translationale Medizin und Pharmakologie ITMP, Immunologie und Allergologie IA, Berlin | Vorstandsmitglied (Schatzmeister), Urtikaria Network e.\u202fV. UNEV; Vorstandsmitglied (Schatzmeister), European Mast cell and Basophil Research Network e.\u202fV. EMBRN; Vorstandsmitglied (Schatzmeister), Kompetenznetzwerk Mastozytose e.\u202fV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf ExternalRef removed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}